Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Echaniz-Laguna, A.
Right arrow Articles by Tranchant, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Echaniz-Laguna, A.
Right arrow Articles by Tranchant, C.
NEUROLOGY 2005;64:1458-1460
© 2005 American Academy of Neurology


Brief Communications

A family with early-onset and rapidly progressive X-linked spinal and bulbar muscular atrophy

A. Echaniz-Laguna, MD, E. Rousso, MD, M. Anheim, MD, M. Cossée, MD, PhD and C. Tranchant, MD, PhD

From the Département de Neurologie (Drs. Echaniz-Laguna, Rousso, Anheim, and Tranchant), Hôpital Civil de Strasbourg, and INSERM U-692 (Dr. Echaniz-Laguna) and Service de Diagnostic Génétique (Dr. Cossée), Faculté de Médecine, CHRU de Strasbourg, France.

Address correspondence and reprint requests to Dr. A. Echaniz-Laguna, Département de Neurologie, Hôpital Civil de Strasbourg, 1 Place de l’Hôpital, BP426, 67091 Strasbourg, France; e-mail: Echaniz-Laguna{at}medecine.u-strasbg.fr

Spinal and bulbar muscular atrophy (SBMA) is an X-linked, late-onset neuroendocrine disorder resulting from an expansion of a CAG repeat in the androgen receptor gene. Reported here is a detailed phenotypic study in a series of seven patients from the same family with SBMA with 50 to 54 CAG repeats, juvenile onset (mean age at onset 13 years [8 to 15 years]), and rapid progression leading to compromised ambulation in the mid-20s.


Received August 30, 2004. Accepted in final form January 13, 2005.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.